Three patient deaths linked to neuromuscular drugs developed by Sarepta Therapeutics (NASDAQ:SRPT) have drawn regulatory scrutiny on the viral vector used in the company’s gene therapy platform ...
Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...
On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...
Clinical Trials Arena on MSN
Sarepta terminates Hansa-partnered gene therapy combination trial
Sarepta and Hansa formed the partnership in 2020 to determine if Idefirix could broaden the patient population for Elevidys.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
FILE - The name and logo of Sarepta Therapeutics is displayed on the company's headquarters, Monday, July 28, 2025, in Cambridge, Mass. WASHINGTON (AP) — The Food and Drug Administration said Friday ...
WASHINGTON – Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a ...
WASHINGTON (AP) — Drugmaker Sarepta Therapeutics (SRPT) said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the ...
CHMP issued a negative opinion on Elevidys for Duchenne patients aged 3–7 despite secondary gains in motor function. Elevidys has treated over 900 DMD patients, but EMA and FDA raise concerns over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback